focus -WSS

focus

author：explore 2025-10-02 04:20:35 Page View：4633

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： NIH confirmation hearing shows politicization of research
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

Cuban government calls US nuclear submarine stop a 'provocative escalation'

LiveTheUSSPasadenareturnstoNavalBasePointLoma,SanDiego,Mar.30,2017afterasix-monthdeploymenttotheWest